Catalio Capital Management LP Takes Position in Dyne Therapeutics, Inc. $DYN

Catalio Capital Management LP bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 519,715 shares of the company’s stock, valued at approximately $10,166,000. Dyne Therapeutics makes up about 1.9% of Catalio Capital Management LP’s holdings, making the stock its 24th biggest holding.

A number of other large investors have also modified their holdings of the stock. Creative Planning grew its stake in shares of Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after buying an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Dyne Therapeutics by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after purchasing an additional 1,440 shares during the last quarter. Caxton Associates LLP boosted its holdings in Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after purchasing an additional 1,627 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Dyne Therapeutics by 9.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock valued at $315,000 after purchasing an additional 2,108 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN opened at $19.20 on Thursday. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of -5.96 and a beta of 1.09. The stock has a 50 day moving average of $18.27 and a 200-day moving average of $18.10.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) EPS. As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on DYN. Evercore set a $33.00 price target on Dyne Therapeutics in a report on Friday, May 15th. Sanford C. Bernstein increased their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Morgan Stanley reduced their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, HC Wainwright reduced their price target on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.85.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 83,219 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the sale, the director directly owned 7,962 shares of the company’s stock, valued at approximately $144,749.16. This represents a 91.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas Kerr sold 1,564 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $28,715.04. Following the sale, the insider directly owned 170,042 shares in the company, valued at approximately $3,121,971.12. This represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders acquired 9,000 shares of company stock worth $156,800 and sold 1,559,462 shares worth $29,814,746. 9.46% of the stock is currently owned by insiders.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.